It has been a difficult year for ASX financials stock Navigator Global Investments Ltd (ASX: NGI). 

Navigator is a holding company – one that holds interests in other companies. 

It describes itself as an alternative asset management company with diverse partnerships across investment styles, product types, and client bases. 

The Company has 29 Partner Firms (of which 17 form the NGI Stable Growth Portfolio), all of which are established alternative asset managers who operate businesses diversified across investment style, product type and client base.

Year to date, its share price has fallen approximately 20%. 

However, Morgan’s has updated its outlook following the company’s Assets Under Management Update.

What did the company report?

Last week, Navigator Global Investments announced: 

• Ownership-adjusted AUM increased by 6% to USD33.6 billion in Q4, up 21% over the last 12 months
• NGI Strategic AUM up 3% to over USD13 billion
• Total Partner Firm AUM up 7% to USD104 billion.

Speaking on the results, the company said ongoing geopolitical uncertainty, interest rate volatility and changing market conditions continue to create both opportunities and challenges for alternative investment strategies.

Looking to FY27, the company said there is a focus on continued AUM growth across LHP and NGI Strategic in Q4 provides a solid platform entering FY27, supplemented by the expected contributions from the NGI Stable Growth Portfolio.

Morgan’s updated view 

Yesterday, this ASX financials stock closed trading at $2.38 per share. 

The team at Morgans provided commentary on the company following its AUM release. 

NGI has released its June 2026 (4Q26) AUM update. We saw this as another broadly solid quarter, marked by a +6% increase in group ownership-adjusted AUM despite volatile markets, and with continued robust quarterly net flows into Lighthouse (+US$690m). 

We revise our NGI FY26F/FY27F EPS by +1%/-2%/-4%, with higher AUM forecasts offset by slightly lower operating margin assumptions. Our price target is reduced to A$3.13 (previously A$3.39). With >20% upside remaining to our PT, we maintain our BUY recommendation.

Despite lowering its price target, the updated target price from Morgans indicates a 31% upside for the ASX financials stock. 

Morgans isn’t the only broker with an optimistic view for this company. 

Recently, the team at Macquarie has a price target on the company of $3.28 along with an outperform rating. 

Macquarie said the company has a strong platform entering FY27. 

The post Broker tips more than 30% upside for this ASX financials stock appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Macquarie tips three ASX finance companies to return better than 30%

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

WiseTech Global Ltd (ASX:WTC) shares have been one of the most painful holdings on the ASX over the past year.

The logistics software company was once an undisputed market darling. Today, it is a battleground stock.

So when will WiseTech shares finally bottom out?

Let’s dig in.

Why WiseTech shares have crashed

The damage for ASX investors has been severe.

WiseTech shares are down roughly 50% in 2026 and around 70% over the past 12 months.

They remain a long way below their 52-week high of $121.31.

Curiously, the problem is not the underlying business, as demand for WiseTech’s CargoWise platform remains solid. As a result, the company is still profitable and still growing.

The real issue is governance.

Investors grew uneasy about scrutiny surrounding founder Richard White. Recent reports have emerged of an Australian Federal Police investigation into White. The allegations centre on claims that he exploited a woman’s immigration and financial situation and provided false information on a visa application.

The complaint reportedly came from a former WiseTech cleaner.

Markets can cope with bad news, but what they cannot stand is uncertainty. This uncertainty has weighed heavily on WiseTech shares.

It is also not the first time White has been caught up in scandal. He previously stepped down as CEO after a wave or reports about secret relationshps with women linked to the company. Another scandal involved allegations that he used company shares and company-related arrangements in ways that were not fully transparent.

What could help WiseTech shares bottom out?

A few things would need to fall into place.

First, the company has moved to clean up its governance. White stepped down as Chair, although he remains on the board as an Executive Director. Raelene Murphy has taken over as Independent Chair.

Bell Potter views that appointment as a positive move. The broker has retained a buy rating and $71.75 price target on WiseTech shares, arguing that the stock looks cheap on an FY27 EV/EBITDA multiple of around 15 times.

That compares to roughly 27 times for rival TechnologyOne Ltd (ASX: TNE).

Second, investors want proof in the numbers, and the FY26 full-year result in August looms as a key catalyst.

A solid result with reassuring FY27 guidance could help the shares find a floor. Resolution of the legal matters surrounding White would help, too.

Until then, expect the volatility to continue.

Foolish takeaway

So, when will WiseTech shares bottom out?

Nobody can call the exact low.

The business itself still looks strong, and brokers see substantial upside from here, but sentiment will likely stay volatile until the governance cloud lifts.

For patient investors, the coming FY26 result could be the moment WiseTech shares finally turn a corner.

The post When will WiseTech shares bottom out? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Sigma Healthcare, Wisetech Global, CBA shares
• Why WiseTech shares could rocket 100%
• 5 things to watch on the ASX 200 on Monday
• Are Macquarie, Qantas, and WiseTech shares buys?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares rose 2.77% and delivered total returns, including dividends, of 7% in FY26.  

Here, we review three fresh buy, hold, and sell calls from expert market analysts.

Weebit Nano Ltd (ASX: WBT)

The Weebit Nano share price soared 414% in FY26 to finish at $8.35 per share.

This was a vastly different performance to many of its peers, which suffered major declines amid a broader tech sector rout. 

Weebit develops advanced semiconductor memory technology.

Mark Elzayed from Investor Pulse reckons there’s more growth ahead for this ASX tech share.

He explains his buy rating on The Bull this week:

Licensing deals with Texas Instruments and onsemi have contributed to company performance. Revenue guidance of $10 million in full year 2026 and a recent capital raising of $102 million fortifies the balance sheet for artificial intelligence and research development.

The shift towards a recurring royalty model generates long term operating leverage.

Momentum and news flow are positive, although the multi year path from licence to royalty income remains the key execution risk.

Metals X Ltd (ASX: MLX)

The Metals X share price ripped 142% to close out FY26 at $1.32.

Elzayed has a hold rating on this ASX materials share.

He explained:

The company is Australia’s largest tin producer. It has a 50 per cent equity interest in the Renison tin operation in Tasmania.

Revenue of $285 million in full year 2025 was up 30 per cent on the prior corresponding period.

However, much of this tin market tightness and consolidation now appears priced into the stock.

The stock is already reflecting a bullish structural tin thesis.

So, in our view, MLX is better suited to holding than buying at these levels.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price fell 29% in FY26 amid a savage healthcare sector downturn. 

However, the stock price of this medical imaging software provider has been recovering strongly since hitting a 52-week low of $107.75 in February.

Pro Medicus shares are up by more than 70% since hitting that floor.

The broader healthcare sector pivoted on 3 June and is also rapidly rising.

Tony Locantro from Alto Capital has a sell recommendation on this ASX 200 healthcare share.

Locantro explained:

The company recently delivered an outstanding first half result in full year 2026. Underlying earnings before interest and tax was up 29.7 per cent and revenue was up 28.4 per cent amid securing more than $A280 million in new contract wins.

Despite these exceptional fundamentals, the company’s premium valuation reflects high market expectations and leaves limited room for disappointment.

While Pro Medicus remains a best-in-class business with strong long term prospects, the current risk-reward balance supports a view to trim holdings at current levels.

The post Buy, hold, sell: Weebit Nano, Metals X, Pro Medicus shares appeared first on The Motley Fool Australia.

More reading

• Up 149% in a year, why this surging ASX 300 tech stock is still a good buy today
• Up 75%, are Pro Medicus shares still a good buy now?
• Why WiseTech shares could rocket 100%
• Where to invest $10,000 in ASX 200 shares in July
• Buy, hold, sell: Pro Medicus, Worley, and ResMed shares

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.